Tools & Diagnostics Recommendations

Viveve Medical Inc.

Josh Jennings, Cowen & Co. (5/11/18) "VIVE improved traction with its hybrid direct distributor sales model in select countries in Europe and gained new regulatory approvals in three Latin American countries."

3D Signatures Inc.

BioTuesdays (2/20/18) "DXD remains on track to complete all phases of the test development and analytical validation by April 2018."

Reliq Health Technologies Inc.

Chris Parry, Equity Guru (10/5/17) "RHT now has 1000 patients into their system from two customers, and expect somewhere between 2000 and 2500 to be added next month."

Viveve Medical Inc.

Brian Marckx, Zacks Equity Research (8/21/17) "One of the major operational items of interest since VIVE's Q1 update is an agreement with InControl Medical LLC."

3D Signatures Inc.

BioTuesdays Publishing Co. (4/4/17) "DXD successfully completing internal analytical assay validation for its Hodgkin's Lymphoma test."

Magdalena Kegel, Alzheimer's News Today (3/22/17) "DXD has developed a simple cheek swab to identify patients with Alzheimer's disease."

Etienne Moshevich, Alphastox.com (3/2/17) "I wanted to send out a quick update on DXD after two tremendous announcements last week that I believe the market totally missed, which is where we see a major buying opportunity."

Shane Matte, BioTuesdays (2/23/17) "The validation program for DXD's Hodgkin's lymphoma test (Telo-HL) is under way."

Jennifer Poland, BioTuesdays (12/7/16) "Preliminary results suggest DXD has a promising molecular imaging technology with potential to improve the management of AC patients who present with multiple lung lesions."

Alphastox.com (11/15/16) "DXD is one of my top picks for the year and through 2017."

Viveve Medical Inc.

Brian Marckx, Zacks Equity Research (10/13/16) "VIVE continues to make substantive progress towards their quest to commercialize the Viveve System in the U.S."

3D Signatures Inc.

James West, Midas Letter (9/7/16) "DXD is a diagnostic technology platform that analyzes changes in telomere structures within DNA to determine aspects and characteristics of deadly diseases like cancer and Alzheimer's Disease."

Viveve Medical Inc.

Anthony Vendetti, Maxim Group (6/21/16) "VIVE is well-positioned to gain regulatory clearances in additional countries, which should lead to the Viveve System gaining further traction."

Brian Marckx, Zacks Equity Research (6/15/16)

Anthony Vendetti, Maxim Group (4/27/16) "The positive results of VIVE's VIVEVE I clinical trial builds upon the two previous clinical studies conducted in the U.S. and Japan."

Gregory Chodaczek, Sterne Agee (4/22/16)

Aethlon Medical Inc.

Kayt Sukel, Fortune (9/10/15) "TIME Magazine named AEMD's Hemopurifier one of the best inventions of 2014."

Nobilis Health Corp.

Canacccord Genuity's Morning Coffee (6/9/15) "HLTH has added its its second ancillary services resume stream of the quarter."

StemCells Inc.

Henry McCusker, RegMed Investors (4/16/15) "STEM expects to release six-month interim Phase 2 data later this year."

Cancer Genetics Inc.

RedChip Companies Inc. (12/16/14) "Pappajohn's show of faith in CGIX speaks volumes about its potential."

Dr. Yi Chen, Aegis Capital (12/5/14) "We believe CGIX's revenues will continue to grow in coming quarters."

Thomas Pfister, RedChip Companies Inc. (11/10/14) "CGIX's Q3/14 revenue grew to $3.22M, representing 90% YOY growth."

NeoGenomics Laboratories

Debjit Chattopadhyay, ROTH Capital Partners (9/30/14) "The new COO's expertise could be a key asset in NEO's product launch."

ImpediMed Ltd.

Scott Power, Morgans (9/5/14) "IPD has had a transformational event; we increase our price target for the company."

Matthijs Smith, Canaccord Genuity (9/3/14) "IPD's major milestone has secured the expanded market; we are increasing our target price."

Cancer Genetics Inc.

Dr. Ram Selvaraju, Aegis Capital (9/3/14) "CE marking allows CGIX's FHACT to be sold freely within the European Economic Area."

NeoGenomics Laboratories

Debjit Chattopadhyay, ROTH Capital Partners (8/21/14) "For NEO, we expect test volume growth of ~25% in 2014, ~18% in 2015."

Debjit Chattopadhyay, ROTH Capital Partners (8/15/14) "NEO bolstered its balance sheet with ~$30M via a secondary offering."

Cancer Genetics Inc.

Dr. Ram Selvaraju, Aegis Capital (8/14/14) "CGIX has sufficient capital to fund operations to break even status."

Sung Ji Nam, Cantor Fitzgerald (8/14/14) "We continue to remain optimist on CGIX in the near to medium term."

Amarantus BioScience Holdings Inc.

Jason Napodano, Seeking Alpha (8/6/14) "A rapid and economical test like AMBS' LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials."

NeoGenomics Laboratories

Debjit Chattopadhyay, ROTH Capital Partners (8/4/14) "NEO has an extensive track record of growing test volume and high client-retention rates."

The Life Sciences Report interview with Debjit Chattopadhyay (7/24/14) "Watch out for NEO; it is significantly undervalued given the opportunities that lie ahead."

Tony Schwartz, Seeking Alpha (7/23/14) "In Q2/14, NEO posted record revenue of $20.7M, up 32% from Q2/13."

Grant Zeng, Zacks Small-Cap Research (7/21/14) "NEO is becoming America's premier cancer testing laboratory."

Amanda Murphy, William Blair (7/18/14) "We are encouraged by NEO's volume growth of 40% in Q2/14."

Robert Wasserman, Dawson James Securities (7/18/14) "Investors in NEO have a lot to look forward to in the future."

Amanda Murphy, William Blair (7/11/14) "NEO's newly expanded NGS menu solidifies the company's market position."

Cancer Genetics Inc.

Jerry Isaacson, LifeSci Advisors (7/1/14) "CGIX's two acquisitions should lead to stable revenue growth."

Verisante Technology Inc.

Christian Glennie, Edison Investment Research (6/30/14) "Potential FDA clearance for VRS' Aura is a key near-term catalyst."

Cancer Genetics Inc.

Sung Ji Nam, Cantor Fitzgerald (6/26/14) "CGIX progresses still with new commercial and clinical collaborations."

NeoGenomics Laboratories

Amanda Murphy, William Blair (6/23/14) "NEO's Q2/14 revenue is expected to be $20–$20.5M (about 30% growth)."

Cancer Genetics Inc.

Dr. Ram Selvaraju, Aegis Capital (6/9/14) "CGIX entered into a partnership with AstraZeneca CAMCAR."

NeoGenomics Laboratories

Debjit Chattopadhyay, ROTH Capital Partners (6/9/14) "Our 2015 above-consensus NEO estimates could become the consensus."

Verisante Technology Inc.

Brian Marckx, Zacks Small-Cap Research (6/5/14) "Cancer Research accepted VRS' Aura study analysis for publication."

Cesca Therapeutics Inc.

The Life Sciences Report Interview with Jason Kolbert (6/4/14) "I think that 2015 will be transformational, as KOOL gets ready to show us top-line data."

Cancer Genetics Inc.

Thomas Pfister, RedChip Companies Inc. (6/4/14) "Meaningful revenues from CGIX's FHACT could be seen in Q3/14."

Verisante Technology Inc.

Christian Glennie, Edison Investment Research (6/2/14) "A key, near-term catalyst for VRS is 501(k) FDA clearance for Aura."

Cancer Genetics Inc.

Jerry Isaacson, LifeSci Advisors (5/16/14) "CGIX's revenue increased by 17% and test volume by 45% compared to the same period in 2013."

OPKO Health Inc.

Rohit Vanjani, Oppenheimer & Co. (5/16/14) "We believe OPK's 4Kscore will serve as a better guide for physicians in assessing high-grade prostate cancer."

Cancer Genetics Inc.

Dr. Ram Selvaraju, Aegis Capital (5/15/14) "CGIX's announced acquisition could lead to future growth."

NeoGenomics Laboratories

Debjit Chattopadhyay, ROTH Capital Partners (5/12/14) "We initiate coverage on NEO with a Buy rating."

Verisante Technology Inc.

Brian Marckx, Zacks Small-Cap Research (5/6/14) "VRS' Aura continues to be recognized as one of the leading novel medical technologies throughout the world."

Foundation Medicine Inc.

Zarak Khurshid, Wedbush (5/5/14) "We are reaffirming our Outperform rating on FMI."

NeoGenomics Laboratories

Grant Zeng, Zacks Small-Cap Research (4/24/14) "We continue to rate NEO's shares Outperform."

Amanda Murphy, William Blair (4/23/14) "NEO's ability to expand its gross margin, win new accounts and beat projections is encouraging."

The Life Sciences Report Interview with Grant Zeng (4/17/14) "There is great potential for NEO to grow in the future."

BioLife Solutions Inc.

Henry McCusker, Scimitar Equity (4/16/14) "BLFS achieved significant growth in sales of its proprietary HypoThermosol and CryoStor biopreservation media products."

Cancer Genetics Inc.

Jerry Isaacson, LifeSci Advisors (4/14/14) "CGIX launched a new test to detect mutations in the CALR gene."

Verisante Technology Inc.

Brian Marckx, Zacks Small-Cap Research (4/10/14) "VRS closed a private placement for gross proceeds of $481K."

Cancer Genetics Inc.

Jerry Isaacson, LifeSci Advisors (4/1/14) "CGIX has several ways to tap an estimated $6B lab testing market."

Sung Ji Nam, Cantor Fitzgerald (4/1/14) "We are initiating coverage on CGIX with a Buy rating."

Dr. Ram Selvaraju, Aegis Capital (3/27/14) "Gross margins for CGIX's base business could double in 18–24 months."

OPKO Health Inc.

Rohit Vanjani, Oppenheimer & Co. (3/13/14) "We are initiating coverage of OPK with an Outperform rating; the diagnostic products represent the nearest-term opportunity."

Tech Guru, Seeking Alpha (3/10/14) "After VNRX closed its capital placement raising $3M, the company has ample cash."

Cancer Genetics Inc.

The Life Sciences Report Interview with Ben Haynor (3/5/14) "The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal."

NeoGenomics Laboratories

Debjit Chattopadhyay, Emerging Growth Stocks (3/4/14) "NEO could generate $5.5–12M for FY/15 and FY/16 from its Covance deal."

OPKO Health Inc.

Eun Yang, Jefferies & Co. (2/28/14) "Preclinical pharmacokinetic data for OPK's FVIIa-CTP are encouraging."

NeoGenomics Laboratories

The Life Sciences Report Interview with Debjit Chattopadhyay (2/27/14) "NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level."

Grant Zeng, Zacks Small-Cap Research (2/20/14) "NEO reported record revenue for Q4/13, the highest in its history."

Drew Jones, Stephens Inc. (2/14/14) "NEO is a very attractive investment; we are initiating coverage."

Cancer Genetics Inc.

Chris Bunge, Seeking Alpha (2/11/14) "CGIX has positioned itself to benefit from the transition of traditional diagnostics to genomic-based testing."

Dr. Ram Selvaraju, Aegis Capital (2/10/14) "CGXI is a leader in the molecular diagnostics field with the ability to generate high-margin revenue."

LabStyle Innovations Corp.

Jason Napodano, Zacks Small-Cap Research (1/22/14) "We are hoping for U.S. full device clearance for DRIO's Dario by the end of 2014."

BioLife Solutions Inc.

PropThink, Seeking Alpha (1/21/14) "2014 will be a key year for BLFS as it moves closer to operating profitability."

Charles Fox, Seeking Alpha (1/13/14) "OPK is priming itself for an extended run of the bulls."

NeoGenomics Laboratories

Amanda Murphy, William Blair (1/8/14) "We are initiating coverage on NEO with an Outperform rating."

Verisante Technology Inc.

The Life Sciences Report Interview with Brian Marckx (12/19/13) "VRS's Aura device for noninvasive skin cancer detection is superior in accuracy and much faster."

Cancer Genetics Inc.

Thomas Pfister, RedChip Companies Inc. (12/17/13) "CGIX is accelerating its sales and marketing strategy."

LabStyle Innovations Corp.

The Life Sciences Report Interview with Ram Selvaraju (12/5/13) "DRIO is developing a very interesting approach to diagnostics at the level of data capture."